135 related articles for article (PubMed ID: 14594107)
1. Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans.
Benso A; Gottero C; Prodam F; Gauna C; Destefanis S; Filtri L; van der Lely AJ; Deghenghi R; Ghigo E; Broglio F
J Endocrinol Invest; 2003 Jul; 26(7):599-603. PubMed ID: 14594107
[TBL] [Abstract][Full Text] [Related]
2. Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans.
Gottero C; Prodam F; Destefanis S; Benso A; Gauna C; Me E; Filtri L; Riganti F; Van Der Lely AJ; Ghigo E; Broglio F
Growth Horm IGF Res; 2004 Oct; 14(5):382-7. PubMed ID: 15336231
[TBL] [Abstract][Full Text] [Related]
3. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
[TBL] [Abstract][Full Text] [Related]
4. Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans.
Prodam F; Benso A; Gramaglia E; Lucatello B; Riganti F; van der Lely AJ; Deghenghi R; Muccioli G; Ghigo E; Broglio F
Neuropeptides; 2008 Feb; 42(1):89-93. PubMed ID: 18061663
[TBL] [Abstract][Full Text] [Related]
5. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans.
Broglio F; Arvat E; Benso A; Gottero C; Prodam F; Grottoli S; Papotti M; Muccioli G; van der Lely AJ; Deghenghi R; Ghigo E
J Clin Endocrinol Metab; 2002 Aug; 87(8):3783-90. PubMed ID: 12161511
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
[TBL] [Abstract][Full Text] [Related]
7. The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing's disease.
Giordano R; Picu A; Bonelli L; Broglio F; Prodam F; Grottoli S; Muccioli G; Ghigo E; Arvat E
Eur J Endocrinol; 2007 Oct; 157(4):393-8. PubMed ID: 17893252
[TBL] [Abstract][Full Text] [Related]
8. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
Arvat E; Di Vito L; Lanfranco F; Broglio F; Giordano R; Benso A; Muccioli GP; Deghenghi R; Ghigo E
J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
[TBL] [Abstract][Full Text] [Related]
9. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans.
Broglio F; Koetsveld Pv Pv; Benso A; Gottero C; Prodam F; Papotti M; Muccioli G; Gauna C; Hofland L; Deghenghi R; Arvat E; Van Der Lely AJ; Ghigo E
J Clin Endocrinol Metab; 2002 Oct; 87(10):4829-32. PubMed ID: 12364482
[TBL] [Abstract][Full Text] [Related]
10. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans.
Di Vito L; Broglio F; Benso A; Gottero C; Prodam F; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Ghigo E; Arvat E
Clin Endocrinol (Oxf); 2002 May; 56(5):643-8. PubMed ID: 12030916
[TBL] [Abstract][Full Text] [Related]
11. Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.
Arvat E; Maccagno B; Ramunni J; Broglio F; Lanfranco F; Giordano R; Benso A; Deghenghi R; Ghigo E
J Endocrinol Invest; 1998 Nov; 21(10):673-9. PubMed ID: 9854683
[TBL] [Abstract][Full Text] [Related]
12. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
Arvat E; Maccagno B; Ramunni J; Giordano R; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
[TBL] [Abstract][Full Text] [Related]
13. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
[TBL] [Abstract][Full Text] [Related]
14. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
[TBL] [Abstract][Full Text] [Related]
16. Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans.
Broglio F; Benso A; Gottero C; Muccioli G; Deghenghi R; Ghigo E; Arvat E
Eur J Endocrinol; 2000 Sep; 143(3):419-25. PubMed ID: 11022186
[TBL] [Abstract][Full Text] [Related]
17. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.
Arvat E; Maccagno B; Ramunni J; Di Vito L; Gianotti L; Broglio F; Benso A; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1998 May; 67(5):310-6. PubMed ID: 9641612
[TBL] [Abstract][Full Text] [Related]
18. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
[TBL] [Abstract][Full Text] [Related]
19. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
[TBL] [Abstract][Full Text] [Related]
20. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
